SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lillys ESMO oncology updates, especially early ovarian-cancer data for Sofe-M with bevacizumab, are drawing attention as investors weigh the pipelines potential to diversify beyond obesity drugs. Traders are also discussing olomorasib lung-cancer findings, while the stocks pullback has prompted mixed reactions about whether the positive pipeline news can support further gains.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillars upcoming quarterly report is the main focus as shares pull back sharply, with traders debating whether strong backlog and data-center power demand can withstand already-high expectations. Some expect further downside if guidance or orders disappoint, while others view the oversold pullback as a buying opportunity.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Phase 2 results for pumitamig plus docetaxel in advanced lung cancer are drawing attention, with traders weighing the reported response rate and progression-free survival against questions about how durable the benefit will be. The reaction is tempered by broader concerns about BioNTechs earlier clinical setbacks and leadership transition.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters volatile share-price swings and pullback are driving debate, with bullish traders buying dips ahead of earnings and pointing to Rev8 lidar deployments and customer partnerships in agriculture, mapping, and autonomous systems. Others question the valuation and pace of commercial adoption, leaving the Physical AI growth case weighed against execution risk.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Positive prostate-cancer trial results are drawing attention, including reports of lower recurrence risk with ERLEADA and a tumor-response signal for an early-stage treatment. Traders see the data as supportive but debate whether it can move the shares meaningfully or is already priced in.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSMs steep selloff has centered on uncertainty over Auvelitys launch for Alzheimers agitation, as prescription data has not shown the acceleration some investors expected; the Nov. 2 Q3 report is widely viewed as a key test of uptake and commercial execution. Some traders fear weak adoption and rising expenses, while others argue that samples and long-term-care prescriptions may be undercounted and remain bullish on the launchs longer-term potential.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is drawing attention ahead of its earnings report as traders debate whether results can halt a sharp selloff tied to weakness in crypto and AI/data-center stocks. Bearish posts fear disappointing results and exposure to CoreWeave, while some investors see the decline as overdone and are positioning for a rebound.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Crypto-market volatility and Coinbases upcoming quarterly report are driving attention, with traders focused on the stocks sharp swings and repeated underperformance versus Bitcoineven during crypto rebounds. Sentiment is largely frustrated and bearish over the weak price action and declining revenue trend, though some expect earnings or a crypto recovery to support a bounce.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos pullback and range-bound trading are drawing attention despite strong AI-networking demand and solid results; traders often point to Piper Sandlers lower price target and concerns that industry growth or valuation may be peaking. Bulls view the weakness as a buying opportunity tied to AI infrastructure spending, while bears remain focused on poor momentum and growth concerns.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention after a prolonged selloff toward 52-week lows, with traders debating analyst downgrades, insider selling, valuation and whether the company can turn its defense-contract pipeline into stronger profits and cash flow. Some see the pullback as overdone given reported contract wins and drone, hypersonics and space demand, while others are cautious ahead of the Q3 report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small-Cap ETFs Beat S&P 500 in 2026: Can the Rally Last?

Small-cap ETFs are beating the S&P 500 in 2026. Will the rally continue? Here's what valuations, earnings and macro trends say.

MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism? 

Equity

Clear Street described sonelokimab’s profile in hidradenitis suppurativa as highly competitive and one that readily supports “blockbuster potential.”


MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts

Moonlake’s lead drug Sonelokimab is being tested across inflammatory conditions, with the biggest near-term focus on hidradenitis suppurativa. 

ONDS Stock Rises Following Acquisition Of Israel-Based Sentry CS

Ondas expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.


Time to fade momentum trade, Jefferies says

Investing.com -- The momentum factor weakened in December, but more downside can be expected in the first quarter, according to a Jefferies strategist.

Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success

This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. FDA.

Invesco Exchange-Traded Fund Trust II - Invesco Dorsey Wright SmallCap Momentum ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The comments followed MoonLake’s release of final Week 52 results from its two pivotal late-stage trials in adults with moderate-to-severe hidradenitis suppurativa.</li><li>MoonLake plans to submit its approval application to the FDA by the end of September.&nbsp;</li><li>Retail investors are now awaiting the data from the company’s trials in psoriatic arthritis.</li></ul> Shares of MoonLake Immunotherapeutics (MLTX) surged 15% on Monday, fueled by strong investor reaction to one-year clinical data on sonelokimab for hidradenitis suppurativa and a bullish note from Clear Street.The stock clocked its best day since early January.<h2 class="st-heading-2">Clear Street Sees ‘Blockbuster Potential’ For MoonLake Drug</h2>Clear Street described the drug’s profile in the skin condition as highly competitive and one that readily supports “blockbuster potential.” The firm kept its ‘Buy’ rating and $70 price target, noting the biologics license application remains on track for a September 30 filing and that management still sees priority review from the U.S. Food and Drug Administration as possible.The comments followed MoonLake’s release of final Week 52 results from its two pivotal late-stage trials in adults with moderate-to-severe hidradenitis suppurativa. Hidradenitis suppurativa is a chronic, painful inflammatory skin condition that causes recurring boils, abscesses, and tunneling wounds, mainly in the armpits, groin, and other skin folds.<h2 class="st-heading-2">MLTX Trial Outcome</h2>Roughly two-thirds of patients in the trials achieved at least a 75% reduction in painful abscesses and nodules without worsening elsewhere, while about one-third reached complete clearance of those lesions, MoonLake said. Around one-quarter hit full inflammatory remission. The outcomes improved further from earlier readouts and compared favorably with results seen for competing treatments at similar time points. Patients also reported meaningful gains in quality of life and pain relief.Safety stayed consistent and favorable through one year, with no new issues. Most patients opted to continue in an open-label extension, and early data from adolescents looked encouraging as well, the company said.MoonLake plans to submit its approval application by the end of September, including data from both adults and teens.<h2 class="st-heading-2">How Did MLTX Retail Traders React?</h2>On Stocktwits, retail sentiment around MLTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the company’s market capitalization rising as much as $5 billion by year's end, following the submission of an application to the FDA and a priority review. The company currently has a market cap of about $1.63 billion<stembedurl>https://www.stocktwits.com/IronManResurrection/message/657099192</stembedurl>Another user highlighted the company’s other near-term catalysts, including data from two late-stage studies of sonelokimab in psoriatic arthritis. The primary results from the two trials are expected in mid-2026 and in the second half of 2026, respectively.<stembedurl>https://www.stocktwits.com/thezat/message/657088197</stembedurl>According to data from Koyfin, 11 of the 15 analysts covering MLTX rate it ‘Buy’ or higher, while two rate it ‘Hold’ and two ‘Sell.’ The stock has a 12-month average price target of $27.62, which represents a potential upside of about 25% from the stock’s last close.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> has gained 84% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/entx-stock-on-track-for-best-day-in-over-5-years-whats-driving-rally/cZKM5L5R79E">ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Clear Street described sonelokimab’s profile in hidradenitis suppurativa as highly competitive and one that readily supports “blockbuster potential.”

Invesco Dorsey Wright SmallCap Momentum ETF

MoonLake Immunotherapeutics

Vanguard Health Care ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$103.36
Prev Close	$103.74
Open	$103.10
Dividend Yield	N/A
50-Day Moving Average	$109.13
Beta	N/A
Avg. Volume	7,079.86
PE Ratio	N/A

52-Week High	$127.77
52-Week Low	$88.62
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

DWAS Fundamentals